The Daily Hit: Today’s Cannabis News Briefs

Here are today’s cannabis news briefs for March 29, 2018:

Emblem Corp.

Emblem Corp. (EMC) announced that it has entered into an agreement with Shoppers Drug Mart to become its medical cannabis provider, pending Health Canada’s approval of Shoppers Drug Mart’s application to become a licensed producer. Under the agreement Emblem will provide Shoppers Drug Mart with branded medical cannabis products, which is to be sold online due to government restrictions on retail pharmacies selling medical cannabis.“From the very beginning we’ve been very focused on being a leader in the medical cannabis space, not only from the production side, but also when it comes to physician and patient education,” commented Nick Dean, CEO of Emblem Corp. “Today’s deal with Shoppers Drug Mart helps to solidify that and positions us well to be a world leader of cannabis for medical purposes.”

Organigram Holdings

Organigram Holdings (OGI) announced today that it has accepted the resignation of Denis Arsenault as Chairman of the Board. Arsenault will continue to providethe company guidance on an ad hoc basis. Filling the vacant position will be Peter Amirault, who currently serves as lead director. “During his tenure with Organigram, Peter has demonstrated strong leadership skills and excellent business acumen” Arsenault said.”I am certain that he will continue to steward the Company going forward with a view to organizational excellence”.

Veritas Pharma Inc.

Veritas Pharma Inc. (VRT) announced today the closing of a private placement of units, valued at $1.5 million. According to the terms of the offering, the company will issue three million units of the company. One unit of the company is defined as one common share and one share purchase warrant for $0.50 per share. Additionally, each share purchase warrant will allow the holder to purchase an extra share for $0.70 per share, for the next three years, following the closing date.“The closing of the private moves the Company forward as we will fully be financed to execute on our plans on the continuation of human trials and to keep an eye on the market for additional acquisition opportunities,” stated Veritas CEO, Dr. Lui Franciosi. “We will also be in a position for next steps with Health Canada on the Company’s ACMPR licensing process.”

William Sumner

William Sumner is a freelance writer specializing in the legal cannabis industry. You can follow William on Twitter @W_Sumner or on Medium.


Leave a Reply

Your email address will not be published. Required fields are marked *

Don't Miss This Week's Groundbreaking News

Join the thousands of subscribers who stay informed with GMR's exclusive news briefs delivered directly to your inbox every Friday afternoon.

We respect your privacy. See our privacy policy.


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 3 days

We will be live blogging from all week. Head to the website – link in bio – if you didn’t m…

@GreenMarketRpt – 3 days

⁦@PelorusEquityGr⁩ Upsizes Offering To $1 Billion

Back to Top

Don't Miss This Week's Groundbreaking News

Join the thousands of subscribers who stay informed with GMR's exclusive news briefs delivered directly to your inbox every Friday afternoon.

We respect your privacy. See our privacy policy.